Lilly-Verve deal sends gene editing stocks higher
Source: SeekingAlpha
2025-06-17 10:29:37 ET
More on Eli Lilly, Verve Therapeutics
- Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
- Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
- Eli Lilly: If You Don't Buy On Weight Loss Promise Now, You Probably Never Will
- Biggest stock movers Tuesday: Solar stocks, VERV, and more
- 4 stocks to watch on Tuesday: JBL, TMUS, LLY and YUM
Read the full article on Seeking Alpha
For further details see:
Lilly-Verve deal sends gene editing stocks higher
Editas Medicine Inc.
NASDAQ: EDIT
EDIT Trading
-3.81% G/L:
$2.5683 Last:
588,088 Volume:
$2.60 Open:
EDIT Latest News
March 09, 2026 07:00:00 am
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
EDIT Stock Data
$174,737,401
95,568,668
0.4%
71
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
